- Numinus Wellness Inc. (NUMI) has launched its ketamine for chronic and serious medical illness program in Utah, British Columbia, and Quebec
- Numinus uses psychedelic-assisted therapies alongside mainstream clinical practices
- The company intends to expand the new program to other clinics in the next few months
- It will be presenting a documentary in Salt Lake City on November 8th to support its work
- Also, the Novamind acquisition is on track with a recent clinic consolidation for the Murray and Salt Lake City locations
- Numinus Wellness Inc. (NUMI) is up 3.77 per cent, trading at $0.27 per share as of 12:18 p.m. ET
Numinus Wellness (NUMI) has launched its ketamine for chronic and serious medical illness program in Utah, British Columbia, and Quebec.
The company uses psychedelic-assisted therapies alongside mainstream clinical practices, and it intends to expand the new program to other clinics in the next few months.
Numinus’ program will specifically offer ketamine-assisted therapy alongside additional community support targeted at improving patients’ physical, emotional, mental and spiritual suffering caused by their illness.
Dr. Paul Thielking, Chief Science Officer of Numinus, commented,
“Many patients develop adjustment disorders, including depression and anxiety… Ketamine-assisted therapy has significant evidence showing efficacy in addressing these symptoms, and Numinus recognizes the opportunity to alleviate suffering while expanding our model of accessible care to more populations.”
As a method of supporting its therapies, Numinus will be presenting a documentary called Dosed 2 in Salt Lake City on November 8th.
In other news, since Numinus’ acquisition of Novamind earlier this year, its integration stayed on track, including the latest consolidation of the Murray and Salt Lake City clinics to streamline clinic operations and enhance the patient experience.
Numinus Wellness Inc. (NUMI) is up 3.77 per cent, trading at $0.27 per share as of 12:18 p.m. ET.